HMBD-002, a non-depleting, high-affinity anti-VISTA antibody, possesses key design features enabling robust anti-tumor activity in preclinical models, positioning it as a potentially important new ...
SINGAPORE, June 26, 2025 (GLOBE NEWSWIRE) -- Hummingbird Bioscience, a biotherapeutics company discovering and developing transformative medicines for hard-to-treat diseases, today announced that it ...
This trial is looking at a new drug called HMBD-001 for solid cancers that have spread into the surrounding tissue or to another part of the body. The trial is for people who can’t have standard ...
HOUSTON and SINGAPORE, Sept. 13, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today ...
VISTA blockade with HMBD-002 reprograms tumor associated macrophages and promotes cytotoxic T-cell response in preclinical studies HMBD-002 in combination with anti-PD-1 treatment shows enhanced ...
SAN DIEGO & HOUSTON & SINGAPORE--(BUSINESS WIRE)--Hummingbird Bioscience (“Hummingbird Bio”), a data-driven precision biotherapeutics company discovering and developing transformative biologic ...
BACKGROUND The frequency of twin births has increased dramatically since the 1970s in nearly all developed countries. This upsurge poses a public health challenge because multiple pregnancies are ...
Percheron Therapeutics obtains exclusive worldwide rights to Hummingbird Bioscience's anti-VISTA mAb for further clinical development Hummingbird Bioscience stands to receive up to USD 290 million in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback